GlobeNewswire

GridGain Unveils Keynote Schedule for Fourth Annual In-Memory Computing Summit North America

Del

Oracle Becomes Platinum Conference Sponsor

FOSTER CITY, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- GridGain® Systems, provider of enterprise-grade in-memory computing solutions based on Apache® Ignite™, today announced the keynote speaker schedule for the fourth annual In-Memory Computing Summit® North America, taking place October 2-3, 2018 at the Hyatt Regency San Francisco Airport. Industry luminaries from ING Belgium, Wellington Management, Oracle, SNIA and GridGain Systems will discuss the evolution of in-memory computing technology and how organizations are leveraging in-memory computing to obtain the speed and scalability necessary for their digital transformation, omnichannel customer experience, Big Data and Fast Data initiatives. GridGain today also announced that Oracle has become a Platinum conference sponsor.

The In-Memory Computing Summit North America 2018 is the only in-memory computing conference focusing on the full range of in-memory computing-related technologies and solutions. The theme of this year’s conference is “Powering the Digital Enterprise with In-Memory Computing.” Conference speakers will discuss topics including in-memory computing use cases related to machine learning and deep learning, the Internet of Things, and other applications requiring Big Data to be ingested, processed and acted upon in real-time. Attendees will learn about the role in-memory computing is playing in the digital transformation of enterprises in industry that span financial services, software, fintech, e-commerce, retail, online business services, healthcare, travel, telecom and other major industries.

Keynote Speakers

Tuesday, October 2

Abe Kleinfeld, President & CEO, GridGain Systems – “In-Memory Computing – Unlocking the Digital Future” – 9:25 a.m. to 9:55 a.m.
All companies, regardless of the industry they serve, are rapidly becoming software companies in their own right, creating a real-time digital twin that virtually models their physical world. The competitive advantage gained by early adopters promises to be transformational and will dramatically improve the market agility of these companies as we progress toward a digital world.

David Follen, Chapter Lead, ING Belgium – “Embracing the Service Consumption Shift in Banking” – 10:00 a.m. to 10:30 a.m.
Legacy banking systems are not tailored for the drastic shift in consumer habits and service consumption. We will see how ING uses in-memory computing platforms to ensure a smooth transition for its customers.

Wednesday, October 3

Arthur Sainio, Co-Chair, SNIA Persistent Memory and NVDIMM Special Interest Group and Director, Product Marketing, SMART Modular Technologies – “Persistent Memory Advances” – 9:25 a.m. to 9:45 a.m.
Persistent Memory technologies being deployed today, including NVDIMMs, and those that are coming will revolutionize development and management tools, platforms, and applications. Find out what matters, how we got here, where we are going, and how the Storage Networking Industry Association (SNIA) is advancing Persistent Memory.

Rafique Awan, Vice President and Principal at Wellington Management – "Optimized In-Memory IBOR Architecture in a Cloud Environment Using Apache Ignite” – 9:50 a.m. to 10:10 a.m.
This session will discuss how Wellington Management has leveraged the GridGain In-memory computing platform to implement an HTAP architecture for its Investment Book of Record (IBOR), a single source of truth for all investment holdings information, providing consistent, timely, and accurate position and exposure information that helps the front office make investment decisions.

Tirthankar Lahiri, Vice President, Data and In-Memory Technologies at Oracle – “In-Memory Database Architectures at Oracle” – 10:15 a.m. to 10:30 a.m.
This session will focus on how in-memory computing technology supports Computer Systems Software, such as in operating systems, database systems, and storage management products, by enabling scalable and fault-tolerant systems with emphasis on high availability, high performance and ease of use. The focus will be on emerging hardware trends, such as chip-level multiprocessor technology, increasing memory density and disk-drive capacity, increasing flash-memory density and other non-volatile memory technology, and assessing the impact of these trends on systems software designs.

Raffle for Complimentary Passes
Enter the weekly raffle for a free General Admission Pass to the conference. Visit the conference website raffle page to enter the drawing.

Sponsorships
The In-Memory Computing Summit North America 2018 is sponsored by leading technology vendors. Current sponsors include:

  • Platinum Sponsors – Oracle, GridGain Systems
  • Gold Sponsor – ScaleOut Software
  • Silver Sponsors – Hazelcast, Neeve Research, Heimdall Data
  • Association Sponsors – Apache Software Foundation, Storage Networking Industry Association (SNIA)
  • Media Sponsors – IT for CEOs & CFOs, ITRtv, ODBMS.org, Packt

About the In-Memory Computing Summit
The In-Memory Computing Summits in Europe and North America are the only industry-wide events tailored to in-memory computing-related technologies and solutions. They are the perfect opportunity to connect with technical IT decision makers, IT implementers, and developers who make or influence purchasing decisions in the areas of in-memory computing, Big Data, Fast Data, IoT and HPC. Attendees include CEOs, CIOs, CTOs, VPs, IT directors, IT managers, data scientists, senior engineers, senior developers, architects and more who make or influence purchasing decisions about in-memory computing, Big Data, Fast Data, IoT and HPC solutions. The Summits are unique forums for networking, education and the exchange of ideas — ideas that power the new world and future of Fast Data. For more information, visit https://imcsummit.org and follow the event on Twitter @IMCSummit.

About GridGain Systems
GridGain Systems is revolutionizing real-time data access and processing by offering an in-memory computing platform built on Apache® Ignite™. GridGain solutions are used by global enterprises in financial, software, e-commerce, retail, online business services, healthcare, telecom and other major sectors, with a client list that includes ING, Sberbank, Finastra, IHS Markit, Workday, and Huawei. GridGain delivers unprecedented speed and massive scalability to both legacy and greenfield applications. Deployed on a distributed cluster of commodity servers, GridGain software can reside between the application and data layers (RDBMS, NoSQL and Apache® Hadoop®), requiring no rip-and-replace of the existing databases, or it can be deployed as an in-memory transactional SQL database. GridGain is the most comprehensive in-memory computing platform for high-volume ACID transactions, real-time analytics, web-scale applications, continuous learning and HTAP. For more information, visit  gridgain.com .

CONTACT:
Terry Erisman
GridGain Systems
terisman@gridgain.com
(650) 241-2281

GridGain and the In-Memory Computing Summit are trademarks or registered trademark of GridGain Systems, Inc. Apache, Apache Hadoop, Hadoop, Apache Ignite, and Ignite are trademarks of The Apache Software Foundation. All other product and company names herein may be trademarks of their registered owners.

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Brookfield Asset Management Announces Results of Annual and Special Meeting of Shareholders17.6.2019 12:55:00 CESTPressemelding

BROOKFIELD, NEWS, June 17, 2019 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (TSX: BAM.A, NYSE: BAM, Euronext: BAMA) today announced that at the company’s annual and special meeting of shareholders held on June 14, 2019 in Toronto, over 85% of Class A Limited Voting Shares (“Class A Shares”) voted in favour of a new management share option plan. In addition, at the meeting all eight nominees proposed for election to the board of directors by holders of Class A Shares and all eight nominees proposed for election to the board of directors by the holder of Class B Limited Voting Shares (“Class B Shares”) were elected. Detailed results of the vote for the election of directors are set out below. Management received the following proxies from holders of Class A Shares in regard to the election of the eight directors nominated by this shareholder class: Director Nominee Votes For % Votes Withheld % M. Elyse Allan 731,503,129 99.60 2,926,448 0.40 Angela F. Braly 730,750,957 99.50 3,67

VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivotal Phase 3 Study of Sci-B-Vac®17.6.2019 12:00:00 CESTPressemelding

Both co-primary endpoints successfully met – including non-inferiority in all adults age ≥18 years, and superiority in adults age ≥ 45 years Seroprotection rates four weeks post-3rd vaccination of Sci-B-Vac® vs. Engerix-B® were statistically significantly higher in key subgroup analyses of adults age ≥ 18 years No safety signals observed – safety and tolerability consistent with known profile of the vaccine With positive PROTECT data, pending successful completion of CONSTANT study, submissions of BLA/MAA for approval in U.S., Europe, and Canada expected to begin mid-year 2020 VBI to host conference call and webcast today, Monday, June 17, 2019 at 8:00 AM ET CAMBRIDGE, Mass., June 17, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced positive top-line results from the randomized, double-blind, pivotal Phase 3 study, PROTECT, designed to

VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac®16.6.2019 18:00:00 CESTPressemelding

CAMBRIDGE, Mass., June 16, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, will host a conference call and webcast tomorrow morning, June 17, 2019, at 8:00 AM ET. Management looks forward to reviewing top-line data from PROTECT, one of two pivotal Phase 3 studies for Sci-B-Vac®, the company’s trivalent hepatitis B vaccine. Conference Call and Webcast Details The live webcast and slide presentation can be accessed via the Events/Presentations page in the investors section of the company’s website, https://www.vbivaccines.com/investors/events-presentations/, or by clicking this link: https://edge.media-server.com/m6/p/7ryhzgu2. A replay of the webcast will be archived on the company’s website for 90 days following the live conference call. To listen to the live conference call, please dial: - Toll-free U.S. & Canada Dial-In: (866) 602-1050 - Internat

Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress15.6.2019 16:00:00 CESTPressemelding

CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in an oral presentation today at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA); 5 of the C3+ wAIHA patients

Carpenter Technology and BMT Aerospace Combine Expertise in Redesign and Production of Additively Manufactured Aerospace Component14.6.2019 15:17:00 CESTPressemelding

LE BOURGET, France, June 14, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE:CRS) and Belgium-based BMT Aerospace today announced their cooperation in the development of an additively manufactured (AM) aerospace pinion, using Carpenter Technology’s Custom 465® Stainless. BMT Aerospace and its subsidiary BMT Additive initiated the project by partnering with Carpenter Technology to produce a redesigned pinion. The redesign project was initiated to enable the benefits of additive manufacturing using high quality, printable material that would attain the high-performance expectations for the application. “BMT Aerospace strongly believes in the disruptive potential of additive manufacturing and its possibilities in aerospace,” explained Ewald Goossens, Business Unit Manager of BMT Additive. “As a small player in the market, we strongly believe in cooperation opportunities like these, where each partner can rely and build on a project, starting from its own expertise. Our spe

Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors14.6.2019 13:00:00 CESTPressemelding

Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolle